PK-Sim® Modules

Modular design offers flexible handling of pharmacokinetic research projects

Both PK-Sim® software packages are designed within a modular architecture and contain the following entities (click here to view enlarged picture of modules integrated in the respective PK-Sim® packages):

    
   
                  

 

Depending on the package purchased these modules are either integrated or can be upgraded at any time. For extending your PK-Sim® version just contact our technical support.

Species Modules

top of page

PK-Sim® can simulate the pharmacokinetics in seven different species (mice, rats, mongrel dogs, beagles, minipigs, monkeys and humans). In both the PK-Sim® Pre-Clinical and the PK-Sim® Clinical package all species are available.

Absorption Modules

top of page

Since PK-Sim® version 3.0 this module has been available as a basic element implemented in all three PK-Sim® packages. The Absorption Module simulates the gastro-intestinal transit and absorption process and serves the needs of scientists involved in biopharmaceutics and formulation development. It is possible to simulate active transport in the intestine (transmembrane influx or efflux, Pgp-like efflux) as well as metabolism processes (multiple linear or saturable Michaelis-Menten) taking place in the gut wall. Furthermore, different release kinetics (e.g. for controlled release) can be modeled selecting different predetermined or user definable release functions for oral application.

Distribution Modules

top of page

Model parameters (organ/plasma partition coefficients, permeabilities) are calculated from substance specific input parameters and can be adjusted independently. Since version 4.0 of PK-Sim® the Rodgers and Rowland Model for a more accurate prediction of partition coefficients of ionized compounds is included. This model takes electrostatic interactions of drugs with acidic phospholipids present in the cellular membrane into account, which is the reason why pK and pH values are included in the calculation of partition coefficients.

Metabolism & Excretion Modules

top of page

Multiple metabolism and elimination processes in various organs and compartments can be simulated using this add-on module. For example, biliary excretion can be described, allowing a realistic description of drugs that are subject to enterohepatic circulation.

PK-PD Module

top of page

This module is an extension of PK-Sim® enabling the description of pharmacodynamic effects and thus the simulation of dose-response relationships. As in conventional PK-PD modeling, a pharmacodynamic effect in dependence of the drug concentration can be defined. Simulated concentration-time profiles for all organs are obtained, in addition to experimental plasma profiles, which particularly help researchers during the late optimization phase and preclinical development to identify specific effects (e.g. the relevance of active transport processes) and to guide the experimental efforts, saving time and money. The PK-PD module is available with the PK-Sim® Clinical package.

PK-Pop Module

top of page

The PK-Pop module allows for the creation and simulation of a realistic virtual population to assess the pharmacokinetic variability in a group of humans. At the heart of this module are built in databases containing information about the age and gender dependence of mean values and variability of the relevant anatomical parameters such as body size, organ volume and blood flow (e.g. from the US NHANES III study).The PK-Pop module is available with the PK-Sim® Clinical package.

Clearance Scaling Module

top of page

With this module hepatic, renal and biliary clearances in a child under the age of 18 years can be estimated based on information about clearance values in adults. In vitro ontogeny information as well as in vivo data of compounds, which undergo elimination by a single process, were used to build the clearance scaling module. The Clearance Scaling module is available with the PK-Sim® Clinical package.

 

Quicksearch Quicksearch

December 12, 2011

Published: Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, Part 2: Extension to describe performance of solid dosage forms.

» More

October 20, 2011

Published in Nature: Few inputs can reprogram biological networks

» More

October 14, 2011

Published: Quantifying stability in gene list ranking across microarray derived clinical biomarkers

» More

January 25, 2012

33rd EORTC PAMM Winter Meeting (Pharmacology and Molecular Mechanisms Group of the European Organisation for Research and Treatment of Cancer), Jan 25-28, Puerto de la Cruz, Tenerife, Spain

» More

February 08, 2012

5th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), February 8-11, Barcelona, Spain

» More

March 12, 2012

2012 ASCPT Annual Meeting, March 12-17, National Harbor, MD, USA

» More